Rafael Holdings, Inc.

NYSE RFL

Rafael Holdings, Inc. Price to Earnings Ratio (P/E) on February 07, 2025

Rafael Holdings, Inc. Price to Earnings Ratio (P/E) is NA on February 07, 2025, a NA change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Rafael Holdings, Inc. 52-week high Price to Earnings Ratio (P/E) is 26.57 on February 13, 2024, which is NA below the current Price to Earnings Ratio (P/E).
Rafael Holdings, Inc. 52-week low Price to Earnings Ratio (P/E) is -2.05 on October 11, 2024, which is NA below the current Price to Earnings Ratio (P/E).
Rafael Holdings, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is 4.57.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NYSE: RFL

Rafael Holdings, Inc.

CEO	Mr. William Conkling
IPO Date	March 27, 2018
Location	United States
Headquarters	520 Broad Street
Employees	13
Sector	Real Estate
Industries Health Care REITs Office REITs

Description

Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.

Key trends

Past 5 years